Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04389281 · ClinicalTrials.gov registry record · Phase 1
X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma
A Phase 1 study of Advanced Solid Tumor Cancer, sponsored by Immunolight.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 4
- Study locations
NCT04389281 is a Phase 1 study of Advanced Solid Tumor Cancer that is actively recruiting participants, run by Immunolight. The registered enrollment target is 52 participants. The trial reports 4 study locations across 3 states.
The verdict
NCT04389281, a Phase 1 study of Advanced Solid Tumor Cancer, is actively recruiting participants, sponsored by Immunolight.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 4
- Study locations
Study Summary
In this Phase I trial for subjects with advanced head \& neck cancer, breast cancer, soft tissue sarcoma or melanoma all subjects will receive open label X-PACT treatment as a intra-tumoral injection. The primary objective will be to establish the safety of X-PACT when dosed with 5 intra-tumoral injections of the combination product (the phosphor device and methoxsalen sterile solution and subsequently exposing the tumor to X-ray energy) over a period of 6 weeks (on day D1, D3 and D5 of Week 1, on D1 of Week 2, and a booster on D1 of Week 6). After the week 8 tumor assessment subjects demonstrating stable disease, partial response or unconfirmed progression assessed by iRecist, will be eligible to receive two additional booster treatments 4-6 weeks apart. Treatment will be considered safe provided ≤ 2 out of 12 patients experience a dose-limiting toxicity (DLT) during the 6 weeks after the first intra-tumoral injection. Two expansion cohorts have been added to the study. One for TNBC and one for soft tissue sarcoma. 16 additional subjects will be added in each of the expansion cohorts.
Conditions Studied
Interventions
- COMBINATION_PRODUCT X-PACT
Study Locations (4)
North Carolina
- Levine Cancer Institute - Charlotte
- Duke University - Durham
District of Columbia
- Sibley Hospital - Johns Hopkins University - Washington D.C.
South Carolina
- Prisma Health - Greenville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2021-12-08 |
| Est. Completion | 2029-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04389281
The ClinicalTrials.gov registry entry for NCT04389281 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immunolight, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumor Cancer appearing as the primary indexed condition, and to 1 intervention - of which X-PACT is the first listed.
NCT04389281 reports 4 study locations spanning 3 distinct geographic areas - top geographies include North Carolina, District of Columbia, South Carolina.
Frequently Asked Questions
What is clinical trial NCT04389281 about?
NCT04389281 is a clinical study titled "X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma". In this Phase I trial for subjects with advanced head \& neck cancer, breast cancer, soft tissue sarcoma or melanoma all subjects will receive open label X-PACT treatment as a intra-tumoral injection. The primary objective will be to establish the safety of X-PACT when dosed with 5 intra-tumoral inj...
What is the current status of trial NCT04389281?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2021-12-08. Estimated completion is 2029-03.
What conditions does trial NCT04389281 study?
This clinical trial studies the following conditions: Advanced Solid Tumor Cancer.
What interventions are being tested in trial NCT04389281?
The interventions under investigation include: X-PACT (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04389281?
This trial is sponsored by Immunolight, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04389281 being conducted?
This trial has 4 study locations across District of Columbia, North Carolina, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.